Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director · CEO, President | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RIGEL PHARMACEUTICALS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 273,362 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 2,424 · Balance 273,362 F1: Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 22:59 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 2,424 | $47.50 | $115,140.00 |
DisclosureSEC source: 0000905148-26-004078 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,362 F1 · balance_after: Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:11 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 31,700 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-26-003038 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,700 Underlying: Common Stock · 31,700 shares Expires 2035-01-29 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on June 17, 2026, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On June 17, 2026, it was determined that the performance metric had been met. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 22:01 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 2,424 | $29.86 | $72,380.64 |
DisclosureSEC source: 0000905148-26-002808 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,593 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 22:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 53,915 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000955 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,017 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest quarterly over three (3) years, with the first quarterly vest occurring on March 31, 2026. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 7,607 | $34.62 | $263,354.34 |
DisclosureSEC source: 0000905148-26-000675 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,102 Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 14,110 | $36.01 | $508,101.10 |
DisclosureSEC source: 0000905148-26-000495 · form4.xml · nonDerivative · entry 5 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,709 Read SEC document |
| January 26, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $27.40 | $0.00 |
DisclosureSEC source: 0000905148-26-000495 · form4.xml · derivative · entry 7 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2026-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| January 26, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $27.40 | $0.00 |
DisclosureSEC source: 0000905148-26-000495 · form4.xml · derivative · entry 6 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2026-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F3 · derivative.exercise_date: The shares vested monthly over two (2) years from January 1, 2016. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| January 26, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 35,424 | $37.00 | $1,310,688.00 |
DisclosureSEC source: 0000905148-26-000495 · form4.xml · nonDerivative · entry 4 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,819 Read SEC document |
| January 26, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 40,000 | $27.40 | $1,096,000.00 |
DisclosureSEC source: 0000905148-26-000495 · form4.xml · nonDerivative · entry 3 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| January 26, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 35,211 | $37.00 | $1,302,807.00 |
DisclosureSEC source: 0000905148-26-000495 · form4.xml · nonDerivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,243 Read SEC document |
| January 26, 2026 Filed Feb 4, 2026 21:20 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 40,000 | $27.40 | $1,096,000.00 |
DisclosureSEC source: 0000905148-26-000495 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F2 · balance_after: Includes 1,000 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:26 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 31,700 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-003347 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,700 Underlying: Common Stock · 31,700 shares Expires 2035-01-29 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 31,700 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:56 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000905148-25-000977 · form4.xml · derivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-01-23 F3 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F3 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met. F3 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. Read SEC document |
| March 17, 2025 Filed Mar 20, 2025 00:56 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 26,250 | $0.00 Strike: $35.40 | $0.00 |
DisclosureSEC source: 0000905148-25-000977 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2031-01-27 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 26,250 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 26,250 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 26,250 shares of the Issuer's common stock on January 27, 2021, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $35.40, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 01:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 4,400 | $21.93 | $96,474.40 |
DisclosureSEC source: 0000905148-25-000411 · form4.xml · nonDerivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,454 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 4,952 | $20.92 | $103,600.79 |
DisclosureSEC source: 0000905148-25-000411 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,854 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 63,400 | $0.00 Strike: $22.49 | $0.00 |
DisclosureSEC source: 0000905148-25-000301 · form4.xml · derivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,400 Underlying: Common Stock · 63,400 shares Expires 2035-01-29 F2 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:47 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 42,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000301 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,806 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $21.40 | $0.00 |
DisclosureSEC source: 0000905148-25-000237 · form4.xml · derivative · entry 6 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2025-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $21.40 | $0.00 |
DisclosureSEC source: 0000905148-25-000237 · form4.xml · derivative · entry 5 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2025-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F3 · derivative.exercise_date: The shares vested monthly over two (2) years from January 1, 2015. F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 44,078 | $22.17 | $977,209.26 |
DisclosureSEC source: 0000905148-25-000237 · form4.xml · nonDerivative · entry 4 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,506 Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 45,000 | $21.40 | $963,000.00 |
DisclosureSEC source: 0000905148-25-000237 · form4.xml · nonDerivative · entry 3 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Tax withholdingCommon Stock | 44,078 | $22.17 | $977,209.26 |
DisclosureSEC source: 0000905148-25-000237 · form4.xml · nonDerivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,584 Read SEC document |
| January 24, 2025 Filed Jan 29, 2025 01:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | Exercise / conversionCommon Stock | 45,000 | $21.40 | $963,000.00 |
DisclosureSEC source: 0000905148-25-000237 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · price: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F1 · balance_after: These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. F2 · balance_after: Includes 1,000 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 01:01 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.70 | $0.00 |
DisclosureSEC source: 0000905148-24-003282 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-26 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met. Read SEC document |
| August 30, 2024 Filed Sep 5, 2024 00:36 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0000905148-24-002512 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2030-02-06 F1 · derivative.exercise_price: The Reporting Person was granted a stock option with a performance-based condition with respect to 32,500 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met. F1 · shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 32,500 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on August 30, 2024, the date the determination was made that the performance metric had been met. F1 · derivative.underlying_shares: The Reporting Person was granted a stock option with a performance-based condition with respect to 32,500 shares of the Issuer's common stock on February 6, 2020, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $24.20, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On August 30, 2024, it was determined that the performance metric had been met. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:15 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000905148-24-000849 · form4.xml · derivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-01-23 F2 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. F3 · derivative.exercise_date: The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. Read SEC document |
| February 28, 2024 Filed Mar 2, 2024 00:15 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0000905148-24-000849 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-01-26 F1 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 26, 2023. Thus, the exercise price of this option is $1.87 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met. F3 · derivative.exercise_date: The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:18 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 30,545 | $1.14 | $34,821.30 |
DisclosureSEC source: 0000905148-24-000445 · form4.xml · nonDerivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,036,629 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 01:18 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 22,349 | $1.13 | $25,261.07 |
DisclosureSEC source: 0000905148-24-000445 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,067,174 F1 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $1.13 to $1.135. Upon request, the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission staff, full information regarding the shares sold at each such separate price. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:17 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000905148-24-000308 · form4.xml · derivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2034-01-23 F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 23, 2024, subject to the Reporting Person's continuous service to the issuer through each such period. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 02:17 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000308 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,089,523 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 1, 2024, with the first annual vest occurring on February 1, 2025. F2 · balance_after: Includes 8,810 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 21:30 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | SaleCommon Stock | 20,340 | $1.75 | $35,595.00 |
DisclosureSEC source: 0001140361-23-005036 · form4.xml · nonDerivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680,713 F3 · kind: These shares were sold to cover tax withholding due upon vesting of Restricted Stock Units. Such "sales to cover" were automatically effected to satisfy tax withholding obligations and do not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 26, 2023 Filed Jan 31, 2023 02:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001140361-23-003442 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-24 F1 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 200,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On January 26, 2023, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on January 26, 2023, the date the determination was made that the performance metric had been met. Read SEC document |
| January 26, 2023 Filed Feb 7, 2023 21:30 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001140361-23-005036 · form4.xml · derivative · entry 3 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2033-01-26 F4 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2023, subject to the Reporting Person's continuous service to the issuer through each such period. Read SEC document |
| January 26, 2023 Filed Feb 7, 2023 21:30 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-005036 · form4.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,701,053 F1 · shares: The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2023, with the first annual vest occurring on February 1, 2024. F2 · balance_after: Includes 9,277 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:30 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001140361-22-047671 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-24 F1 · shares: The Reporting Person was granted an option with a performance-based condition with respect to 200,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On December 28, 2022, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on December 28, 2022, the date the determination was made that the performance metric had been met. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 20:15 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001140361-22-033612 · form4.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-01-23 F1 · shares: The reporting person was granted an option with a performance-based condition with respect to 300,000 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On September 14, 2022, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on September 14, 2022, the date the determination was made that the performance metric had been met. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:36 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | PurchaseCommon Stock | 1,000,000 | $0.69 | $688,400.00 |
DisclosureSEC source: 0001567619-22-012778 · doc1.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391,776 F1 · price: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions ranging from $0.67 to $0.70. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each such separate price. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 01:43 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001567619-22-001779 · doc1.xml · derivative · entry 2 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-01-24 F3 · derivative.exercise_date: The shares of common stock subject to the option vest monthly over four (4) years from the vesting commencement date of January 1, 2022, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 01:43 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-001779 · doc1.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,776 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from February 1, 2022, with the first annual vest occurring on February 1, 2023. F2 · balance_after: Includes 18,257 shares acquired under the Issuer's stock purchase plan. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 23:01 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001567619-21-019428 · doc1.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-01-23 F1 · shares: The reporting person was granted a performance-based option to purchase 300,000 shares of common stock on January 23, 2019. Thus, the exercise price of this option is $2.00 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On November 4, 2021, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on October 25, 2021, the date the performance metric had been met. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 22:22 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 162,500 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001179110-21-004126 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2030-02-06 F1 · shares: The reporting person was granted a performance-based option to purchase 162,500 shares of common stock on February 6, 2020. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On April 1, 2021, it was determined that the performance metric had been met. F2 · derivative.exercise_date: The option was fully vested on April 1, 2021, the date the performance metric had been met. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 23:49 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option(right to buy) · Derivative | 525,000 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0001179110-21-000982 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2021, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:12 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (right to buy) · Derivative | 650,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001179110-20-001348 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2020, subject to the reporting person's continuous service to the issuer through each such period. Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 01:06 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 237,500 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-011938 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,500 Underlying: Common Stock · 237,500 shares Expires 2028-01-24 F1 · derivative.exercise_price: The reporting person was granted a performance based option to purchase 237,500 shares of common stock on January 24, 2018. Thus,the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. F1 · derivative.exercise_date: The reporting person was granted a performance based option to purchase 237,500 shares of common stock on January 24, 2018. Thus,the exercise price of this option is $4.49 (the closing price of the issuer's common stock on Nasdaq the day prior to the date of grant). In light of the performance-based vesting condition of this grant, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 18, 2019, it was determined that the performance metric had been met. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 23:17 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 237,500 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001179110-19-004205 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,500 Underlying: Common Stock · 237,500 shares Expires 2028-01-24 F1 · derivative.exercise_date: On January 24, 2018, the reporting person was granted a performance based option to purchase 237,500 shares of common stock based on a specific performance metric. On March 20, 2019, it was determined that the performance metric had been met. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:17 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantEmployee Stock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001179110-19-000931 · edgar.xml · derivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 23:12 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | PurchaseCommon Stock | 114,000 | $2.63 | $300,002.40 |
DisclosureSEC source: 0001179110-18-010749 · edgar.xml · nonDerivative · entry 1 RODRIGUEZ RAUL R · CIK 0001190279 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,519 F1 · price: The price reported in Column 4 is the weighted average price. These shares were purchased in multiple transactions ranging from $2.61 to $2.64. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the issuer, or the Securities and Exchange Commission, full information regarding the shares purchased at each such separate price. F2 · balance_after: Includes 2,502 shares that were purchased by the Reporting Person on June 29, 2018 under the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.